Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants

15 Jul 2021

Abstract excerpt

SARS-CoV-2 variants have emerged with enhanced pathogenicity and transmissibility, and escape from pre-existing immunity, suggesting first-generation vaccines and monoclonal antibodies may now be less effective. Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants. First, we affinity matured an angiotensin-converting enzyme 2 (ACE2) decoy protein, achieving 1000-fold...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34265018
DOI: 10.1371/journal.ppat.1009544

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsPMID 34265018Read ↗

Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsSemantic proximity Read ↗

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variantsSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo.Semantic proximity Read ↗

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoVSemantic proximity Read ↗

A Soluble ACE2 Protein Improves Survival and Lowers Viral Titers in a Lethal Mouse Model of SARS-CoV-2 Infection with the Delta VariantSemantic proximity Read ↗

Redirection of SARS-CoV-2 to Phagocytes by Intranasal sACE2-Fc as a Universal Decoy Confers Complete Prophylactic ProtectionSemantic proximity Read ↗

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read ↗

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivoSemantic proximity Read ↗

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read ↗

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read ↗

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.